Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Belviq presented a modest recovery of a bit more than 3%, higher than previous week’s number, which delivered a 10% drop on the heels of a discount card that expired on March 31st. Another industry tracker, Symphony Health, declared this week’s sales as flat (increased 0.5%) from previous week. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), shares after opening at $6.72 moved to $6.76 on last trade day and at the end of the day closed at $6.68. Company price to sales ratio in past twelve months was calculated as 17.99 and price to cash ratio as 6.60. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), showed a positive weekly performance of 12.08%.
On April 16, 2014, Pharmaceutical giant, Inovio Pharmaceuticals Inc (NYSEMKT:INO), is scaling up its leadership restructuring process having announced the appointment of E.J.Brandreth as the company’s new Vice President for quality. Inovio Pharmaceuticals Inc (NYSEMKT:INO), shares advanced 7.11% in last trading session and ended the day on $2.56. Inovio Pharmaceuticals Inc (NYSEMKT:INO), return on equity ratio is recorded as -144.44% and its return on assets is -92.70%. Inovio Pharmaceuticals Inc (NYSEMKT:INO), yearly performance is 319.67%.
Exelixis, Inc. (Nasdaq:EXEL) reported financial results for the quarter ended March 31, 2014. Exelixis, Inc. (NASDAQ:EXEL), shares moved down 5.68% in last trading session and was closed at $3.32, while trading in range of $ 3.21 – 3.51. Royal Bancshares of Exelixis, Inc. (NASDAQ:EXEL), year to date (YTD) performance is -45.84%.
Gilead Sciences, Inc. (NASDAQ:GILD), has recently released a new drug called Sovaldi that has created a revolution in the treatment of hepatitis C. Vice President of Gilead, Gregg Alton recently said that Sovaldi has led to effective treatment of hepatitis C leading, and further has significantly contributed in reducing the cost of the drug. Gilead highlights that the old therapies cost around $150k-$200k involving longer treatments. However the new treatment with Sovaldi helps in the treatment of hepatitis C in just three months at $1000/ day. Gilead Sciences, Inc. (NASDAQ:GILD), weekly performance is 5.16%. On last trading day company shares ended up $77.71. Gilead Sciences, Inc. (NASDAQ:GILD), distance from 50-day simple moving average (SMA50) is 2.91%. Analysts mean target Price for the company is $99.04.